China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)

Market Cap	9.51B -31.5%
Revenue (ttm)	2.06B +18.7%
Net Income	112.70M -71.6%
EPS	0.22 -72.2%
Shares Out	504.25M
PE Ratio	85.68
Forward PE	16.16
Dividend	0.22 (1.18%)
Ex-Dividend Date	n/a

Volume	4,835,627
Average Volume	5,264,921
Open	18.33
Previous Close	18.51
Day's Range	18.25 - 18.90
52-Week Range	18.25 - 30.76
Beta	0.21
RSI	27.35
Earnings Date	Mar 21, 2026

About SHE:300294

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 1,938
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300294

Financial Performance

In 2025, SHE:300294's revenue was 2.06 billion, an increase of 18.69% compared to the previous year's 1.73 billion. Earnings were 112.70 million, a decrease of -71.61%.